IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Gold Prices Edge Higher as Markets Await Key U.S. PCE Inflation Data 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Germany’s Economic Recovery Slows as Trade Tensions and Rising Costs Weigh on Growth 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
Oil Prices Rise as Ukraine Targets Russian Energy Infrastructure 
BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague 
Samsung Biologics, South Korea's biotech behemoth, expands its portfolio in a $1.08 billion deal with U.S. pharma titan, Pfizer, marking a landmark in global biotech manufacturing. The enhanced partnership will leverage Samsung's newest facility to produce Pfizer's multiproduct biosimilar portfolio.
This includes a new contract signed with Pfizer, building upon the initial deal established in March. Under the new agreement, Samsung Biologics will manufacture an additional $193 million of Pfizer products.
Additionally, Samsung Biologics will produce Pfizer's multiproduct biosimilar portfolio, encompassing oncology, inflammation, and immunotherapy, with a value of $704 million. The company will extend its manufacturing capabilities to provide Pfizer ample capacity for large-scale production of a multiproduct biosimilar portfolio.
This strategic collaboration will occur at Samsung Biologics' newest facility, Plant 4, in Songdo, South Korea. Completing the 240,000-liter biomanufacturing plant in June 2023 marks a significant milestone in the continued growth of Samsung Biologics.
Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer, expressed his enthusiasm for the partnership, stating they are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe.
These manufacturing partnerships solidify Samsung Biologics' position in the global contract development and manufacturing organization (CDMO) market. As part of its expansion strategy, the company is increasing its production capacity and aims to become a major player in the industry.
The contracts with Pfizer highlight the long-term strategic partnership between the two companies, further establishing Samsung Biologics as a trusted collaborator. The company plans to explore new avenues in overseas markets by considering opening new sales offices to facilitate communication with global customers. With an existing office in New Jersey and a research and development center in San Francisco, Samsung Biologics is set for continued growth on a global scale.
